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ABSTRACT 
The influenza virus has plagued humans for centuries. Recently antiviral medications, 
which shorten the duration of the flu, have been introduced into society. These 
medications along with vaccinations, which try to give the body immunity before the 
virus strikes, help to stop the flu before it attacks the host. The virus, however, replicates 
using host cells and can slightly change itself with each replication, which over time could 
lead to a strain immune to the current antiviral medication and vaccines. However, using 
more preventative measures could help slow the changing strains of the flu virus. Using 
vaccines to stop the virus at the host before it mutates and using antiviral medication 
before the flu starts replicating inside patients are both examples of preventative 
measures. In the future, research must be focused on creating vaccines to limit the need 
for antiviral medication to slow the evolution process of the influenza virus overall.  
 




In an age where medicine has evolved so quickly, the diseases that plague us have been 
forced to adapt, growing stronger as we took our advancements for granted. This has led 
disease-causing bacteria to adapt to modern medicine, creating superbugs that are 
resistant to most antibiotics. It is estimated that if left unchecked, superbugs could cause 
around 10 million deaths per year by 2050.1 However, while the bacteria have evolved to 
fight off medicine, they have been chased by another group of microscopic killers. 
Bacteriophages, better known as phages, are microscopic viruses that target and attack 
bacterial cells. Phages are found everywhere that bacteria live and are highly specific, 
meaning a species of phage tends to attack only one specific bacterial strain or species.2 
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Due to the unprecedented growth of drug resistant bacteria, humans have turned to 
other methods in hopes of fighting these superbugs, and an option being investigated is 
phage therapy. Phage therapy is a medical process in which bacteriophages are 
administered to a patient in order to attack bacteria and rid the body of infection.3 Since 
it is a relatively new field, there has not been enough research done to introduce the 
concept on a wide scale. However, enough work has been done to provide detailed 
isolation and selection methods for specific phages as well as demonstrate high success 
rates in trials run on drug resistant bacteria. This research could lead to phage therapy 
becoming a viable treatment alternative in medicine. 
  
ISOLATION AND SELECTION METHODS 
Phages act differently than antibiotics because while antibiotics tend to be broad and 
can attack both harmful and helpful bacteria, phages specifically target a certain 
bacterial species or strain, which makes them highly specific. This specificity is one of the 
main driving factors as to why phage therapy is successful. Before administration of the 
phage therapy to patients, however, the necessary phages must be gathered and tested 
to guarantee that the correct phages were retrieved to fight a certain strain of bacteria. 
As such, those involved in the development of treatment search areas where phages are 
believed to reside. Since phages lack a uniform distribution, they are often found near 
hospitals, sewage, and natural sources like cow and sheep feces or river and lake water 
due to the large quantity of bacteria living in those areas as well.2, 4-7 After collection, the 
samples go through sterilization by filtering and incubating, as is demonstrated using 
phage 1513, one example out of millions of phages.2, 4-5, 7-8 Researchers centrifuge the 
sample containing phage 1513 to remove unnecessary particles, add  and bacteria to the 
remaining liquid, and incubate the mixture.4 Following this, one of five procedures are 
done to confirm phage presence: the plate (double layer) method, enrichment method, 
spot method, electron microscopy method, or the colorimetric method; however the 
most commonly used procedure is the plate method.2, 5-8 The plate method is done to 
test which phage is present in the sample by placing the liquid sample on a plate of agar 
containing bacteria, preferably an infectious strain, and allowing plaques to form, thus 
showing which phages attacked the bacteria.2, 4, 9 As an added measure if the plate 
method fails, the colorimetric method is based on the tendency of bacteria to reduce a 
molecule called tetrazolium to formazan, which produces a dark red color as the process 
is carried out.2 The colorimetric test functions by having the phages destroy the bacteria, 
preventing the reduction and demonstrating a lack of color, showing what phages are 
present and active depending on which bacteria was killed and stopped producing color.2 
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Nonetheless, any of the other tests can be done to confirm the results of the plate 
method.6 The isolation process is shown in Figure 1. 
Once isolation of the specific phage has been completed through one of the five 
previously mentioned tests, the selection method can take place. This process allows for 
the genome, as well as other characteristics, of the phage to be determined, functioning 
as an identification of the isolated phage. An example of this is shown with phage 1513, 
where growth of the phage during isolation testing shows that the phage grows and 
works best at a neutral pH and low temperatures up to normal body temperature, 
displaying some characteristics found during selection.4 An important factor to 
determine selection of a phage is whether a phage is lytic, meaning that the phage must 
be able to break open the infected bacterial cell to kill it.2, 10 Therefore, the genome of 
such phages must be sequenced if this characteristic, and many other preferred ones are 
found to have a function in phage therapy.2 Researchers must also be certain the newly 
sequenced phage is different or unique enough from previously catalogued phages to 
avoid having lacking effects on chosen bacteria, as similarities between the phages may 
negatively impact treatment.9 Some other possible characteristics that researchers 
search for include affinity to certain bacteria, whether a phage can cause the bacterial 
cells to activate uncontrolled apoptosis or cell death when certain conditions are met to 
make the bacteria kill itself, or how well a phage can lyse bacterial cell walls.2, 8-11 During 
this stage of selection, the genome of the phage can also be modified to better fit the 
objectives of the researchers.12 For example, the genome of an isolated phage can be 
modified to manipulate the genome of the target bacteria by inserting genes that make 
the cells more vulnerable to antibiotics.12 However, this process would serve better as a 
preemptive measure to make the bacteria more susceptible to antibiotics prior to 
infecting a human.12 Even so, it is possible that it could serve as a way to allow better 
synergy between phage cocktails and antibiotics during treatment. 
  
PHAGE THERAPY CASE STUDIES 
Animal-Based Case Studies 
Once the phages are isolated and selected, they are stored until needed to treat specific 
infections. While the treatment is still experimental, tests have been run on both animals 
such as mice, rats, and moth larvae, as well as trials on humans with advanced infections 
and no other remedies with high success rates and promising results.4, 11, 13-15 Tests run on 
mice infected with lethal multidrug resistant K. pneumoniae were given single phage 
doses of phage 1513, which was selected to treat K. pneumoniae, intranasally.4 Following 
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phage therapy, the survival rate went from 0% all the way up to 80% depending on the 
dose given.4 The therapy was also shown to improve tissue damage and reduce the 
effects of infection such as weight loss.4 An upgrade from single phage doses was 
researched through tests on rats with P. aeruginosa, which introduced the use of phage 
cocktails.14 The cocktails used various phages to widen the range of bacteria that could 
be targeted, as well as introduced the possibility of synergizing phage therapy with 
antibiotic treatment to counteract the mutations of bacteria developing phage 
resistance.1, 14 A cocktail of 12 phages were isolated to fight 33 strains of P. aeruginosa, 
killing off all but 2 phage resistant strains.14 However, the phage resistant strains were 
far less infectious than the other strains, and they were treated by the antibiotics that 
were administered alongside the phage cocktail.14 
  
Human-Based Case Studies 
Due to a lack of overall awareness and FDA approval, phage therapy is currently seen as 
an experimental last resort in medicine. As such, human trials are usually done on 
patients that have severe late stage infections where no other form of viable treatment 
has helped improve their condition. In the selected human trials, both patients had 
contracted serious drug resistant infections, as one had developed necrotic sores and 
septicaemia from P. aeruginosa and the other had a worsening pancreatitis condition 
caused by A. baumannii that led to a coma.13, 15 Both patients were administered phage 
cocktails specifically made to treat their infection, which improved their conditions 
drastically through repeated administration of treatment.13, 15 The patient with the P. 
aeruginosa infection had an immediate change in his blood cultures, as they returned 
negative results when tested for presence of bacteria, kidney function had returned, and 
the heavy fever had dissipated.13 The patient with the A. baumannii infection was able to 
successfully wake up from his coma and his condition gradually improved over the course 
of treatment administration.15 A separate in vitro trial took samples from diabetic 
patients that had developed septic wounds and analyzed the pus from the wounds for 
signs of bacterial infections, finding drug resistant strains of P. aeruginosa, K. 
pneumoniae, S. aureus, and E. coli.6 The necessary phages were isolated and applied to 
the infected samples, which were then observed to lower bacterial population density 
between the first 4 to 14 hours of incubation.6 However, after the 14 hours, researchers 
noticed that the bacterial populations began to increase once more, which they 
attributed to either growth of phage resistant bacteria or the inactivation of the phages.6 
Although phage therapy is a viable alternative that has high success rates in both human 
and animal trials, there is still a risk of the targeted bacteria mutating to develop 
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resistance to the phages that attack them as demonstrated previously. Various tests on 
both animals and humans have shown that phage therapy can lead to mutant bacteria 
developing resistance to the phages, which can be fatal if left untreated.1 Even so, the 
development of phage resistance in bacteria does not come without drawbacks. The 
development of phage resistance causes bacteria to lose virulence and resistance to 
antibiotics, which can greatly benefit patients as the bacteria cannot infect as well as 
they could previously.1 This development of phage inactivation and phage resistance, as 
well as the costs of developing phage resistance, should lead to more tests that examine 
the administration of antibiotics alongside the phage therapy to maximize potential 
treatment in the case of a repeat scenario like what happened in this study. 
         
CONCLUSION 
Phage therapy, while still experimental and lacking some research, has proven to be 
extremely effective when treating bacterial infections that were resistant to antibiotics.2-
4, 9, 11, 13-15 In vitro and in vivo trials have shown excellent results, especially when 
combined to make phage cocktails rather than single phage doses.2-3, 11, 13, 15 Treatment 
can be further improved when combining phage cocktails with antibiotics to target any 
remaining bacteria that mutated phage resistance.14 Phage therapy, if given the funding 
and attention needed for more research into collection, testing, and effects on humans 
and safety, could easily become a perfect alternative for treating bacterial infections that 





Figure 1: General process of gathering and isolating phages before selection for 
phage therapy. Phages are gathered in samples from sources containing bacteria such 
as natural water sources, sewage, or near hospitals.2, 4-7 The samples are then filtered and 
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incubated to remove unwanted particles and bacteria, then the phages are isolated using 
one or more of the listed methods before selection.2-11, 13-15 The listed tests allow for 
researchers to isolate phages that target their selected superbug or bacterial strain by 
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